Total Payments
$130,369
2024 Payments
$3,853
Companies
51
Transactions
1,237
Medicare Patients
15,298
Medicare Billing
$1.9M
Payment Breakdown by Category
Other$90,585 (69.5%)
Food & Beverage$21,472 (16.5%)
Travel$10,510 (8.1%)
Consulting$7,500 (5.8%)
Education$301.93 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $90,585 | 41 | 69.5% |
| Food and Beverage | $21,472 | 1,127 | 16.5% |
| Travel and Lodging | $10,510 | 50 | 8.1% |
| Consulting Fee | $7,500 | 3 | 5.8% |
| Education | $301.93 | 16 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amarin Pharma Inc. | $54,258 | 118 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $31,231 | 129 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $19,157 | 195 | $0 (2024) |
| ARALEZ PHARMACEUTICALS US INC. | $9,112 | 21 | $0 (2018) |
| Boston Scientific Corporation | $3,320 | 69 | $0 (2024) |
| CVRx, Inc. | $2,111 | 14 | $0 (2024) |
| Amgen Inc. | $1,634 | 117 | $0 (2024) |
| Abbott Laboratories | $1,249 | 53 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,182 | 60 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $997.55 | 62 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,853 | 134 | CVRx, Inc. ($2,086) |
| 2023 | $2,132 | 144 | E.R. Squibb & Sons, L.L.C. ($371.19) |
| 2022 | $2,223 | 168 | Novartis Pharmaceuticals Corporation ($313.40) |
| 2021 | $2,361 | 170 | AstraZeneca Pharmaceuticals LP ($267.17) |
| 2020 | $9,588 | 116 | Amarin Pharma Inc. ($7,816) |
| 2019 | $27,518 | 134 | Amarin Pharma Inc. ($16,660) |
| 2018 | $30,965 | 159 | Amarin Pharma Inc. ($15,378) |
| 2017 | $51,729 | 212 | Novartis Pharmaceuticals Corporation ($15,767) |
All Payment Transactions
1,237 individual payment records from CMS Open Payments — Page 1 of 50
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | Chiesi USA, Inc. | JUXTAPID (Drug) | Food and Beverage | Cash or cash equivalent | $14.71 | General |
| Category: HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | ||||||
| 12/17/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $14.99 | General |
| Category: Endocrinology | ||||||
| 12/11/2024 | Abbott Laboratories | AVEIR (Device) | Food and Beverage | In-kind items and services | $23.98 | General |
| Category: Cardiac Rhythm Management | ||||||
| 12/11/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $13.65 | General |
| Category: Diabetes | ||||||
| 12/10/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $16.13 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/05/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $5.66 | General |
| Category: Endocrinology | ||||||
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $13.91 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/03/2024 | Abbott Laboratories | MERLIN@HOME (Device) | Food and Beverage | In-kind items and services | $23.28 | General |
| Category: Cardiac Rhythm Management | ||||||
| 11/27/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $17.59 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 11/25/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $7.50 | General |
| Category: Endocrinology | ||||||
| 11/21/2024 | Philips North America LLC | (5044) MCOT (Device) | Food and Beverage | Cash or cash equivalent | $14.02 | General |
| Category: Medical Device | ||||||
| 11/20/2024 | Chiesi USA, Inc. | JUXTAPID (Drug) | Food and Beverage | Cash or cash equivalent | $15.97 | General |
| Category: HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | ||||||
| 11/19/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $14.59 | General |
| Category: Cardiovascular | ||||||
| 11/12/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $14.13 | General |
| Category: Endocrinology | ||||||
| 11/11/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $17.23 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/05/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $15.38 | General |
| Category: Cardiology | ||||||
| 10/31/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $16.49 | General |
| Category: Endocrinology | ||||||
| 10/28/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $3.91 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/24/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $14.18 | General |
| Category: Cardiology | ||||||
| 10/23/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $120.29 | General |
| Category: Endocrinology | ||||||
| 10/23/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.99 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/22/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $15.45 | General |
| Category: Cardiovascular | ||||||
| 10/22/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $1.07 | General |
| Category: Cardiovascular | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $3.96 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/16/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $13.73 | General |
| Category: Endocrinology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 27 | 3,679 | 5,751 | $733,246 | $413,064 |
| 2022 | 28 | 3,884 | 7,745 | $685,325 | $487,678 |
| 2021 | 23 | 4,233 | 7,573 | $775,314 | $570,115 |
| 2020 | 30 | 3,502 | 6,716 | $616,465 | $451,893 |
Total Patients
15,298
Total Services
27,785
Medicare Billing
$1.9M
Procedure Codes
114
All Medicare Procedures & Services
114 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 484 | 1,106 | $134,418 | $93,629 | 69.7% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 216 | 219 | $187,132 | $83,318 | 44.5% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 335 | 349 | $114,325 | $54,990 | 48.1% |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 2023 | 216 | 223 | $54,750 | $42,538 | 77.7% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 188 | 761 | $52,345 | $32,288 | 61.7% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 148 | 148 | $35,341 | $23,663 | 67.0% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 218 | 222 | $32,118 | $11,804 | 36.8% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 483 | 1,010 | $26,610 | $11,462 | 43.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 46 | 59 | $13,726 | $8,314 | 60.6% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 92 | 106 | $12,589 | $7,865 | 62.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 50 | 83 | $9,792 | $7,450 | 76.1% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 785 | 907 | $11,710 | $6,179 | 52.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 24 | 24 | $5,128 | $4,061 | 79.2% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 20 | 20 | $5,492 | $3,888 | 70.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 36 | 56 | $4,754 | $3,480 | 73.2% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 58 | 60 | $8,844 | $3,375 | 38.2% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 19 | 19 | $4,002 | $3,070 | 76.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 19 | 19 | $3,146 | $1,986 | 63.1% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2023 | 24 | 24 | $2,850 | $1,795 | 63.0% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2023 | 42 | 91 | $3,236 | $1,716 | 53.0% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 20 | 21 | $1,767 | $1,342 | 75.9% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 28 | 55 | $2,257 | $1,316 | 58.3% |
| 93295 | Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | Office | 2023 | 18 | 38 | $1,793 | $1,047 | 58.4% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 29 | 29 | $1,120 | $906.48 | 80.9% |
| 90688 | Influenza vaccine, quadrivalent, 0.5 ml dosage | Office | 2023 | 29 | 29 | $2,030 | $572.88 | 28.2% |
About Dr. Avinash Gupta, MD
Dr. Avinash Gupta, MD is a Cardiovascular Disease healthcare provider based in Lakewood, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1265531487.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Avinash Gupta, MD has received a total of $130,369 in payments from pharmaceutical and medical device companies, with $3,853 received in 2024. These payments were reported across 1,237 transactions from 51 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($90,585).
As a Medicare-enrolled provider, Gupta has provided services to 15,298 Medicare beneficiaries, totaling 27,785 services with total Medicare billing of $1.9M. Data is available for 4 years (2020–2023), covering 114 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Lakewood, NJ
- Active Since 09/22/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1265531487
Products in Payments
- Vascepa (Drug) $54,258
- XARELTO (Drug) $31,231
- ENTRESTO (Drug) $18,649
- YOSPRALA (Drug) $9,013
- WATCHMAN (Device) $2,548
- Barostim Neo System (Device) $2,111
- ELIQUIS (Drug) $1,010
- BRILINTA (Drug) $778.99
- EVENITY (Biological) $633.45
- Repatha (Biological) $563.69
- JARDIANCE (Drug) $525.41
- LEQVIO (Drug) $508.20
- CAMZYOS (Drug) $460.84
- (5044) MCOT (Device) $344.00
- VERQUVO (Drug) $330.42
- Pacemakers (Device) $311.95
- FARXIGA (Drug) $310.82
- Confirm Rx (Device) $289.47
- VYNDAQEL (Drug) $281.80
- WATCHMAN Access System (Device) $267.97
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Lakewood
Konstantinos Vlachonassios, M.d, M.D
Cardiovascular Disease — Payments: $81,470
Cardiovascular Disease $81,470
Dr. John Svinarich, M.d., F.a.c.c, M.D., F.A.C.C
Cardiovascular Disease — Payments: $60,231
Cardiovascular Disease $60,231
Dr. Jeffrey Rubinstein, M.d.,F.a.c.c, M.D.,F.A.C.C
Cardiovascular Disease — Payments: $28,567
Cardiovascular Disease $28,567
Dr. John Altman, Md, MD
Cardiovascular Disease — Payments: $25,928
Cardiovascular Disease $25,928
Dr. Isaac Eisenstein, M.d, M.D
Cardiovascular Disease — Payments: $17,269
Cardiovascular Disease $17,269
Dr. Hed Ahmadpour, M.d, M.D
Cardiovascular Disease — Payments: $14,791
Cardiovascular Disease $14,791